Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

GSK criticised over salmeterol study reporting

Reuters report that an American consumer group, Public Citizen, have accused GlaxoSmithKline (GSK) of manipulating data from the Serevent Multicentre Asthma Research Trial (SMART).

The SMART study was a 28 week study initiated in 1996. It found that there was an increased risk of asthma-related death in the Salmeterol arm of the study compared to the control arm according to interim results presented to the Food and Drugs Administration (FDA) in 2003. The full paper has never been published although it is worth noting that many of the patients in the Salmeterol arm of the study were not prescribed steroid inhalers.

Public Citizen have accused GSK of including post-study data relating to adverse events in data submitted to the FDA with the effect of misleading the FDA.

Action: Prescribers need to be aware of this as patients may ask questions about their asthma treatment. UK patients can be re-assured that the trial in America does not mirror UK practice; most patients in the UK are prescribed a steroid inhaler for their asthma.

Share 'GSK criticised over salmeterol study reporting' on Email Share 'GSK criticised over salmeterol study reporting' on Delicious Share 'GSK criticised over salmeterol study reporting' on Digg Share 'GSK criticised over salmeterol study reporting' on Facebook Share 'GSK criticised over salmeterol study reporting' on Google+ Share 'GSK criticised over salmeterol study reporting' on reddit Share 'GSK criticised over salmeterol study reporting' on StumbleUpon Share 'GSK criticised over salmeterol study reporting' on Twitter

atomic-wealth

No Comments to “GSK criticised over salmeterol study reporting”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,431 spam comments.

atomic-wealth
fond-illness
summer